Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.20
STXS's Cash to Debt is ranked lower than
83% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. STXS: 0.20 )
Ranked among companies with meaningful Cash to Debt only.
STXS' s Cash to Debt Range Over the Past 10 Years
Min: 0.16  Med: 0.87 Max: N/A
Current: 0.2
Equity to Asset -0.89
STXS's Equity to Asset is ranked lower than
98% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. STXS: -0.89 )
Ranked among companies with meaningful Equity to Asset only.
STXS' s Equity to Asset Range Over the Past 10 Years
Min: -1.07  Med: -0.05 Max: 0.82
Current: -0.89
-1.07
0.82
F-Score: 2
Z-Score: -32.85
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -9.76
STXS's Operating margin (%) is ranked lower than
71% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. STXS: -9.76 )
Ranked among companies with meaningful Operating margin (%) only.
STXS' s Operating margin (%) Range Over the Past 10 Years
Min: -292.85  Med: -61.34 Max: -15.38
Current: -9.76
-292.85
-15.38
Net-margin (%) -12.60
STXS's Net-margin (%) is ranked lower than
70% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. STXS: -12.60 )
Ranked among companies with meaningful Net-margin (%) only.
STXS' s Net-margin (%) Range Over the Past 10 Years
Min: -289.88  Med: -92.51 Max: -14.86
Current: -12.6
-289.88
-14.86
ROA (%) -21.76
STXS's ROA (%) is ranked lower than
78% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. STXS: -21.76 )
Ranked among companies with meaningful ROA (%) only.
STXS' s ROA (%) Range Over the Past 10 Years
Min: -217.44  Med: -66.90 Max: -18.93
Current: -21.76
-217.44
-18.93
ROC (Joel Greenblatt) (%) -158.10
STXS's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.36 vs. STXS: -158.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
STXS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3377.46  Med: -520.45 Max: -77.3
Current: -158.1
-3377.46
-77.3
Revenue Growth (3Y)(%) -37.40
STXS's Revenue Growth (3Y)(%) is ranked lower than
95% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. STXS: -37.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
STXS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -12.50 Max: 218.5
Current: -37.4
0
218.5
EBITDA Growth (3Y)(%) -76.40
STXS's EBITDA Growth (3Y)(%) is ranked lower than
98% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. STXS: -76.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
STXS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -76.4  Med: -39.40 Max: 19.6
Current: -76.4
-76.4
19.6
EPS Growth (3Y)(%) -63.80
STXS's EPS Growth (3Y)(%) is ranked lower than
98% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. STXS: -63.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
STXS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.8  Med: -33.60 Max: 17.2
Current: -63.8
-63.8
17.2
» STXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

STXS Guru Trades in Q4 2014

Jim Simons 35,400 sh (New)
» More
Q1 2015

STXS Guru Trades in Q1 2015

Charles Brandes 40,000 sh (New)
Jim Simons 157,000 sh (+343.50%)
» More
Q2 2015

STXS Guru Trades in Q2 2015

Jim Simons 186,900 sh (+19.04%)
Charles Brandes 40,000 sh (unchged)
» More
Q3 2015

STXS Guru Trades in Q3 2015

Charles Brandes Sold Out
Jim Simons 172,700 sh (-7.60%)
» More
» Details

Insider Trades

Latest Guru Trades with STXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.42
STXS's P/S is ranked higher than
94% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. STXS: 0.42 )
Ranked among companies with meaningful P/S only.
STXS' s P/S Range Over the Past 10 Years
Min: 0.15  Med: 3.18 Max: 35.43
Current: 0.42
0.15
35.43
Current Ratio 1.00
STXS's Current Ratio is ranked lower than
91% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. STXS: 1.00 )
Ranked among companies with meaningful Current Ratio only.
STXS' s Current Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.12 Max: 5.72
Current: 1
0.61
5.72
Quick Ratio 0.68
STXS's Quick Ratio is ranked lower than
91% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. STXS: 0.68 )
Ranked among companies with meaningful Quick Ratio only.
STXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.90 Max: 5.39
Current: 0.68
0.47
5.39
Days Inventory 212.34
STXS's Days Inventory is ranked lower than
77% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.52 vs. STXS: 212.34 )
Ranked among companies with meaningful Days Inventory only.
STXS' s Days Inventory Range Over the Past 10 Years
Min: 115.43  Med: 192.32 Max: 332.78
Current: 212.34
115.43
332.78
Days Sales Outstanding 63.01
STXS's Days Sales Outstanding is ranked higher than
53% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 64.05 vs. STXS: 63.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
STXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.56  Med: 92.34 Max: 205.12
Current: 63.01
67.56
205.12
Days Payable 82.30
STXS's Days Payable is ranked higher than
66% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. STXS: 82.30 )
Ranked among companies with meaningful Days Payable only.
STXS' s Days Payable Range Over the Past 10 Years
Min: 83.22  Med: 137.35 Max: 230.03
Current: 82.3
83.22
230.03

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.14
STXS's Price/Median PS Value is ranked higher than
98% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. STXS: 0.14 )
Ranked among companies with meaningful Price/Median PS Value only.
STXS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.06  Med: 1.05 Max: 11.02
Current: 0.14
0.06
11.02
Price/Graham Number 0.40
STXS's Price/Graham Number is ranked higher than
93% of the 110 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.30 vs. STXS: 0.40 )
Ranked among companies with meaningful Price/Graham Number only.
STXS' s Price/Graham Number Range Over the Past 10 Years
Min: 0.13  Med: 0.66 Max: 13.63
Current: 0.4
0.13
13.63
Earnings Yield (Greenblatt) (%) -4.85
STXS's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. STXS: -4.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
STXS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.1  Med: 17.30 Max: 22.9
Current: -4.85
3.1
22.9

More Statistics

Revenue(Mil) $38
EPS $ -0.23
Beta4.18
Short Percentage of Float3.49%
52-Week Range $0.54 - 2.97
Shares Outstanding(Mil)21.54

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RJR1.Germany,
Stereotaxis Inc was incorporated in Delaware on June 1990. The Company designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. The core components of the Niobe system have received regulatory clearance in the U.S., Canada Europe, and various other countries. In addition to the Niobe system and its components, the Company also has developed the Odyssey Solution, which consolidates the multiple sources of diagnostic and imaging information found in the interventional lab into a large-screen user interface with single mouse control, which could be connected via a private network line to other interventional labs or to a remote clinical call center. The system also features a remote viewing and recording capability, called Odyssey Cinema, which simultaneously captures procedure data from multiple sources. The tool includes an archiving capability that would allow clinicians to store and replay entire procedures or segments of procedures. This information could be accessed from locations throughout the hospital local area network and over the global Odyssey network providing physicians with a tool for clinical collaboration, remote consultation and training. The Company operates mainly in the U.S., Europe and Asia and it continues to sell its products both within and outside of the U.S. It markets its products in the U.S and internationally through a direct sales force of senior sales specialists, distributors and sales agents, supported by account managers and clinical specialists that provide training, clinical support, and other services to its customers. The markets for medical devices are intensely competitive and are characterized by rapid technological advances, frequent new product introductions, evolving industry standards and price erosion. It faces competition from companies that are developing new approaches and products for use in interventional procedures, including robotic approaches that are directly competitive with its technology. It also faces competition from companies who currently market or are developing drugs, gene or cellular therapies to treat the conditions for which the Company's products are intended.
» More Articles for STXS

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: NBN, EMMS, STXS, FOE, NVTL May 21 2012 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,800 Shares Jan 04 2011 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 05 2010 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,500 Shares May 11 2010 
Stereotaxis Inc. (STXS) CFO Daniel J Johnston buys 10,000 Shares May 10 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) May 07 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 06 2009 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 1,410 Shares Sep 03 2009 
Stereotaxis Inc. Reports Operating Results (10-Q) Aug 07 2009 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,300 Shares Jun 04 2009 

More From Other Websites
Stereotaxis still out of compliance with Nasdaq rules Feb 08 2016
Stereotaxis to Report Fourth Quarter and Full Year 2015 Financial Results on February 22, 2016 Feb 08 2016
STEREOTAXIS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Feb 05 2016
University Medical Center New Orleans Implements Stereotaxis Platform for Advanced Treatment of... Feb 01 2016
University Medical Center New Orleans Implements Stereotaxis Platform for Advanced Treatment of... Feb 01 2016
Stereotaxis and Philips Extend Development Collaboration to Interface Latest Systems Jan 26 2016
Stereotaxis and Philips Extend Development Collaboration to Interface Latest Systems Jan 26 2016
STEREOTAXIS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Jan 22 2016
Edited Transcript of STXS earnings conference call or presentation 3-Nov-15 9:30pm GMT Jan 12 2016
Stereotaxis Initiates Multi-Center Randomized Superiority Study on Ventricular Tachycardia Ablation... Jan 11 2016
Stereotaxis Initiates Multi-Center Randomized Superiority Study on Ventricular Tachycardia Ablation... Jan 11 2016
STEREOTAXIS, INC. Financials Dec 08 2015
Stereotaxis, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 08 2015
Multicenter Study Reveals Improved Long-Term Success Rates With Stereotaxis Technology in... Nov 17 2015
STEREOTAXIS, INC. Files SEC form 10-Q, Quarterly Report Nov 05 2015
STEREOTAXIS, INC. Files SEC form 8-K/A, Other Events Nov 04 2015
Stereotaxis Inc Earnings Call scheduled for 4:30 pm ET today Nov 03 2015
Stereotaxis Reports 2015 Third Quarter Financial Results Nov 03 2015
STEREOTAXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 03 2015
Stereotaxis to Report Third Quarter 2015 Financial Results on November 3, 2015 Oct 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK